November 12th 2024
The initiation of a phase 2 study of the investigational 31-valent pneumococcal conjugate vaccine is expected by the end of January 2025.
Study shows dengue vaccine is safe and effective
October 11th 2024Overall, 2 doses of TAK-003 successfully induced the production of neutralizing antibodies against all 4 dengue serotypes in at least 90% of adults, children, and adolescents, regardless of whether they were seronegative or seropositive at baseline.
Nirsevimab doses for 2024-2025 RSV season can be reserved with new program
February 2nd 2024Nirsevimab was approved by the FDA on July 17, 2023, ahead of the traditional RSV season, though in October, the Centers for Disease Control and Prevention (CDC) recommended it be prioritized for the highest-risk infants amid limited availability.
Recent reports of measles in multiple states
January 25th 2024Tina Tan, MD, FAAP, FIDSA, FPIDS, tells Contemporary Pediatrics, “This is not new and demonstrates what is known, in that if vaccination rates do not stay at a level that is protective, outbreaks of vaccine preventable diseases will occur.”
BNT162b2 COVID vaccine effective in children amid Delta, Omicron periods
January 17th 2024Investigators of a study published in Annals of Internal Medicine concluded that the BNT162b2 COVID-19 vaccine demonstrated efficacy against the Delta and Omicron variants of COVID-19 in children and adolescents, offering new, extended follow-up period data.